AGTC

Biotechnology ResearchFlorida, United States51-200 Employees

AGTC is a clinical-stage biotechnology company that develops gene therapies using a proprietary platform, with an initial focus in ophthalmology. Its lead candidates target inherited, single-gene eye diseases that can significantly affect vision and currently lack effective treatments. The company maintains six ophthalmology development programs across five targets, including XLRS, XLRP, achromatopsia, wet age-related macular degeneration, and blue cone monochromacy. In addition to ophthalmology, AGTC is pursuing two non-ophthalmology programs—alpha-1 antitrypsin deficiency and adrenoleukodystrophy—and is conducting early-stage research into genetic defects in inner-ear cells that may lead to deafness. AGTC emphasizes a targeted approach based on unmet medical need, clinical feasibility, and potential commercial value, supported by a significant IP portfolio and expertise in gene therapy design (capsids, promoters, expression cassettes) as well as formulation, manufacturing, and delivery. The company is based in Alachua, Florida, and employs between 51 and 200 people; its website is agtc.com.

Sign up for free to view info

Email Format Employee directory